RATIONALE: Timeliness is one of six important dimensions of health care quality recognized by the Institute of Medicine. OBJECTIVES: To evaluate timeliness of lung cancer care and identify institutional characteristics associated with timely care within the Veterans Affairs (VA) health care system. METHODS: We used data from a VA nation-wide retrospective chart review and an independent audit of VA cancer programs to examine the association between time to first treatment and potentially explanatory institutional characteristics (e.g., volume of lung cancer patients) for 2,372 veterans diagnosed with lung cancer between 1 January 2002 and 1 September 2005 at 127 VA medical centers. We developed linear mixed effects models to control for clustering of patients within hospitals and we stratified analyses by stage. MEASUREMENTS AND MAIN RESULTS: Median time to treatment varied widely between (23 to 182 d) and within facilities. Median time to treatment was 90 days in patients with stage I or II cancer and 52 days in those with more advanced disease (P < 0.0001). Factors associated with shorter times to treatment included a nonacademic setting and the existence of a specialized diagnostic clinic (in patients with limited-stage disease), performing a patient flow analysis (in patients with advanced disease), and leadership beliefs about providing timely care (in both groups). However, institutional characteristics explained less than 1% of the observed variation in treatment times. CONCLUSIONS: Time to lung cancer treatment in U.S. veterans is highly variable. The numerous institutional characteristics we examined explained relatively little of this variability, suggesting that patient, clinician, and/or unmeasured institutional characteristics may be more important determinants of timely care.
RATIONALE: Timeliness is one of six important dimensions of health care quality recognized by the Institute of Medicine. OBJECTIVES: To evaluate timeliness of lung cancer care and identify institutional characteristics associated with timely care within the Veterans Affairs (VA) health care system. METHODS: We used data from a VA nation-wide retrospective chart review and an independent audit of VA cancer programs to examine the association between time to first treatment and potentially explanatory institutional characteristics (e.g., volume of lung cancerpatients) for 2,372 veterans diagnosed with lung cancer between 1 January 2002 and 1 September 2005 at 127 VA medical centers. We developed linear mixed effects models to control for clustering of patients within hospitals and we stratified analyses by stage. MEASUREMENTS AND MAIN RESULTS: Median time to treatment varied widely between (23 to 182 d) and within facilities. Median time to treatment was 90 days in patients with stage I or II cancer and 52 days in those with more advanced disease (P < 0.0001). Factors associated with shorter times to treatment included a nonacademic setting and the existence of a specialized diagnostic clinic (in patients with limited-stage disease), performing a patient flow analysis (in patients with advanced disease), and leadership beliefs about providing timely care (in both groups). However, institutional characteristics explained less than 1% of the observed variation in treatment times. CONCLUSIONS: Time to lung cancer treatment in U.S. veterans is highly variable. The numerous institutional characteristics we examined explained relatively little of this variability, suggesting that patient, clinician, and/or unmeasured institutional characteristics may be more important determinants of timely care.
Authors: Melissa H Tukey; Jack A Clark; Rendelle Bolton; Michael J Kelley; Christopher G Slatore; David H Au; Renda Soylemez Wiener Journal: Ann Am Thorac Soc Date: 2016-10
Authors: Markus Glatzer; Achim Rittmeyer; Joachim Müller; Isabelle Opitz; Alexandros Papachristofilou; Ioannis Psallidas; Martin Früh; Diana Born; Paul Martin Putora Journal: Eur Respir J Date: 2017-08-24 Impact factor: 16.671
Authors: Amelia W Maiga; Stephen A Deppen; Rhonda Pinkerman; Carol Callaway-Lane; Pierre P Massion; Robert S Dittus; Eric S Lambright; Jonathan C Nesbitt; David Baker; Eric L Grogan Journal: Ann Thorac Surg Date: 2017-10-21 Impact factor: 4.330
Authors: Duc Ha; Andrew L Ries; Philippe Montgrain; Florin Vaida; Svetlana Sheinkman; Mark M Fuster Journal: Respir Med Date: 2018-07-17 Impact factor: 3.415
Authors: F J Gonzalez-Barcala; J A Falagan; J M Garcia-Prim; L Valdes; J M Carreira; A Puga; P Martín-Lancharro; M T Garcia-Sanz; D Anton-Sanmartin; J C Canive-Gomez; A Pose-Reino; R Lopez-Lopez Journal: Ir J Med Sci Date: 2013-10-04 Impact factor: 1.568
Authors: Ryan P Merkow; Karl Y Bilimoria; Karen L Sherman; Martin D McCarter; Howard S Gordon; David J Bentrem Journal: J Oncol Pract Date: 2013-02-26 Impact factor: 3.840